ESR1 peptides vaccine study (Breast Cancer) - Clinical Trial
Email to Participate
diane.pinder@duke.edu
What is the Purpose of this Study?
We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with Estrogen receptor positive (ER+) breast cancer.
What is the Condition Being Studied?
Breast Cancer
Who Can Participate in the Study?
-Adults who:
--Are diagnosed with breast cancer
--Have completed chemotherapy or surgery.
Age Group
Adults
What is Involved?
If you choose to join this study you will:
-Get the study vaccine (ESR1 peptide)
-Return to the Duke Cancer Center for follow-up visits 6-8 times over 10 weeks.
-Be contacted by phone every 12 weeks to see how you are doing
-Have a skin biopsy (piece of skin will be taken) where the study vaccine was injected.
Study Details
Full Title
A Phase I Study of Cancer Peptides plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer
Principal Investigator
Herbert Lyerly
Protocol Number
IRB:
PRO00104868
NCT:
NCT04270149
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email diane.pinder@duke.edu